Last reviewed · How we verify
Adefovir (ADV)
Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.
Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus. Used for Chronic hepatitis B infection, HBV with lamivudine resistance.
At a glance
| Generic name | Adefovir (ADV) |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Nucleotide reverse transcriptase inhibitor |
| Target | Hepatitis B virus DNA polymerase / reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Adefovir dipivoxil is a prodrug that is converted to adefovir, which inhibits hepatitis B virus (HBV) reverse transcriptase and DNA polymerase. By blocking viral DNA synthesis, it reduces HBV replication and viral load in chronically infected patients. It is also active against HIV reverse transcriptase, though primarily developed for HBV.
Approved indications
- Chronic hepatitis B infection
- HBV with lamivudine resistance
Common side effects
- Nephrotoxicity / renal dysfunction
- Headache
- Asthenia
- Abdominal pain
- Elevated creatinine
Key clinical trials
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B (PHASE4)
- Extension Study of Carvedilol RCT Study (NA)
- Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver (PHASE1, PHASE2)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB) (PHASE3)
- A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (PHASE4)
- The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adefovir (ADV) CI brief — competitive landscape report
- Adefovir (ADV) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI